| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Horizon Therapeutics Public Limited Company (NASDAQ: HZNP)
HZNP Technical Analysis
3
| As on 9th Jun 2023 HZNP SHARE Price closed @ 99.25 and we RECOMMEND Buy for LONG-TERM with Stoploss of 85.13 & Buy for SHORT-TERM with Stoploss of 96.67 we also expect STOCK to react on Following IMPORTANT LEVELS. |
HZNPSHARE Price
| Open | 99.30 | Change | Price | % |
| High | 99.97 | 1 Day | -0.17 | -0.17 |
| Low | 99.22 | 1 Week | -0.10 | -0.10 |
| Close | 99.25 | 1 Month | -11.28 | -10.21 |
| Volume | 2664379 | 1 Year | -4.03 | -3.90 |
| 52 Week High 116.36 | 52 Week Low 58.92 | ||||
NASDAQ USA Most Active Stocks
| TSLA | 244.40 | 4.06% |
| TTOO | 0.07 | -12.50% |
| SOFI | 8.18 | 0.74% |
| FFIE | 0.33 | 6.45% |
| PONO | 1.72 | 2.38% |
| AMD | 124.92 | 3.20% |
| IDEX | 0.06 | 0.00% |
| NKLA | 0.70 | 14.75% |
| AMZN | 123.43 | -0.66% |
| AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| HZNP Daily Charts |
HZNP Intraday Charts |
Whats New @ Bazaartrend |
HZNP Free Analysis |
|
|
HZNP Important Levels Intraday
| RESISTANCE | 100.70 |
| RESISTANCE | 100.23 |
| RESISTANCE | 99.95 |
| RESISTANCE | 99.66 |
| SUPPORT | 98.84 |
| SUPPORT | 98.55 |
| SUPPORT | 98.27 |
| SUPPORT | 97.80 |
HZNP Forecast April 2024
| 4th UP Forecast | 133.18 |
| 3rd UP Forecast | 122.3 |
| 2nd UP Forecast | 115.57 |
| 1st UP Forecast | 108.85 |
| 1st DOWN Forecast | 89.65 |
| 2nd DOWN Forecast | 82.93 |
| 3rd DOWN Forecast | 76.2 |
| 4th DOWN Forecast | 65.32 |
HZNP Weekly Forecast
| 4th UP Forecast | 107.88 |
| 3rd UP Forecast | 105.11 |
| 2nd UP Forecast | 103.40 |
| 1st UP Forecast | 101.69 |
| 1st DOWN Forecast | 96.81 |
| 2nd DOWN Forecast | 95.10 |
| 3rd DOWN Forecast | 93.39 |
| 4th DOWN Forecast | 90.62 |
HZNP Forecast2024
| 4th UP Forecast | 214.2 |
| 3rd UP Forecast | 177.33 |
| 2nd UP Forecast | 154.55 |
| 1st UP Forecast | 131.76 |
| 1st DOWN Forecast | 66.74 |
| 2nd DOWN Forecast | 43.95 |
| 3rd DOWN Forecast | 21.17 |
| 4th DOWN Forecast | -15.7 |
Horizon Therapeutics Public Limited Company ( NASDAQ USA Symbol : HZNP )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
HZNP Business Profile
Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The company operates in two segments, Orphan and Inflammation. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI (glycerol phenylbutyrate) oral liquid; PROCYSBI (cysteamine bitartrate) delayed-release capsules and granules for oral use; ACTIMMUNE (interferon gamma-1b) injection for subcutaneous use; BUPHENYL (sodium phenylbutyrate) tablets and powder for oral use; QUINSAIR (levofloxacin) solution for inhalation; and UPLIZNA (inebilizumab-cdon) injection for intravenous use. The company also markets PENNSAID (diclofenac sodium topical solution) for topical use; DUEXIS (ibuprofen/famotidine) tablets for oral use; RAYOS (prednisone) delayed-release tablets for oral use; and VIMOVO (naproxen/esomeprazole magnesium) delayed-release tablets for oral use. It has collaboration agreements with Lupus Research and HemoShear Therapeutics, LLC. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland with additional offices in Deerfield, Illinois; Chicago, Illinois; South San Francisco, California; Washington, D.C.; Gaithersburg, Maryland; Rockville, Maryland; and Mannheim, Germany. Address: Connaught House, Dublin, Ireland, 4
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service